pteridines has been researched along with Osteosarcoma in 6 studies
Osteosarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Osteosarcoma is the most common primary malignant tumor of bone, which frequently occurs in the second decade of life." | 5.37 | BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. ( Brassesco, MS; Montaldi, AP; Morales, AG; Oliveira, JC; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG, 2011) |
| "By using a mouse model of osteosarcoma induced by paratibial injection of cells, we assessed the impact of Smad7 overexpression or SD-208 on tumor growth, tumor microenvironment, bone remodeling, and metastasis development." | 3.80 | Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma. ( Amiaud, J; Bougras, G; Chesneau, J; Heymann, D; Heymann, MF; Lamora, A; Le Deley, MC; Leduc, M; Redini, F; Stresing, V; Talbot, J; Taurelle, J; Verrecchia, F, 2014) |
| " In this study, we tested the second-generation PLK1 inhibitors BI 6727 and GSK461364 in HOS and MG-63 cell lines, both as a single agent and in combination with methotrexate, cisplatin, vinblastine, doxorubicin, or ionizing radiation." | 1.42 | BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments. ( Bogado, RF; Brassesco, MS; de Oliveira, HF; Pezuk, JA; Tone, LG, 2015) |
| "Osteosarcoma is the most common type of primary bone cancer in children and adolescents." | 1.37 | Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo. ( Choy, E; Duan, Z; Harmon, D; Hornicek, FJ; Liu, X; Mankin, H; Yang, C; Yang, S, 2011) |
| "Osteosarcoma is the most common primary malignant tumor of bone, which frequently occurs in the second decade of life." | 1.37 | BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity. ( Brassesco, MS; Montaldi, AP; Morales, AG; Oliveira, JC; Pezuk, JA; Sakamoto-Hojo, ET; Scrideli, CA; Tone, LG, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lund-Andersen, C | 1 |
| Patzke, S | 1 |
| Nähse-Kumpf, V | 1 |
| Syljuåsen, RG | 1 |
| Bogado, RF | 1 |
| Pezuk, JA | 2 |
| de Oliveira, HF | 1 |
| Tone, LG | 2 |
| Brassesco, MS | 2 |
| Lamora, A | 1 |
| Talbot, J | 1 |
| Bougras, G | 1 |
| Amiaud, J | 1 |
| Leduc, M | 1 |
| Chesneau, J | 1 |
| Taurelle, J | 1 |
| Stresing, V | 1 |
| Le Deley, MC | 1 |
| Heymann, MF | 1 |
| Heymann, D | 1 |
| Redini, F | 1 |
| Verrecchia, F | 1 |
| Liu, X | 1 |
| Choy, E | 1 |
| Harmon, D | 1 |
| Yang, S | 1 |
| Yang, C | 1 |
| Mankin, H | 1 |
| Hornicek, FJ | 1 |
| Duan, Z | 1 |
| Morales, AG | 1 |
| Oliveira, JC | 1 |
| Montaldi, AP | 1 |
| Sakamoto-Hojo, ET | 1 |
| Scrideli, CA | 1 |
| Dhondt, JL | 1 |
| Hayte, JM | 1 |
| Millot, F | 1 |
| Klein, R | 1 |
| Blais, JC | 1 |
| Pfleiderer, W | 1 |
6 other studies available for pteridines and Osteosarcoma
| Article | Year |
|---|---|
PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule.
Topics: Bone Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; | 2014 |
BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Bone Neoplasms; Cell Cycle Checkpoints; Cell Cycle | 2015 |
Overexpression of smad7 blocks primary tumor growth and lung metastasis development in osteosarcoma.
Topics: Animals; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Disease Models, Animal; Female; Gene Exp | 2014 |
Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
Topics: Animals; Bone Neoplasms; Cell Cycle Proteins; Cell Division; Cell Growth Processes; Cell Line, Tumor | 2011 |
BI 2536-mediated PLK1 inhibition suppresses HOS and MG-63 osteosarcoma cell line growth and clonogenicity.
Topics: Antineoplastic Agents; Caspase 3; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Chromosomal Ins | 2011 |
2,4-diamino-7-hydroxy-pteridines, a new class of catabolites of methotrexate.
Topics: Adolescent; Adult; Animals; Biotransformation; Child; Child, Preschool; Chromatography, High Pressur | 1991 |